Viatris (VTRS) has drawn fresh investor attention after reporting positive Phase 3 results for VR-205 in Japanese patients with primary IgA nephropathy. This highlights a potential future product opportunity in a high-need kidney disease market.
See our latest analysis for Viatris.
The recent IgA nephropathy data and fresh term loan agreement come after a strong run in the stock, with a 90 day share price return of 24.26% and a 1 year total shareholder return of 86.25%. This suggests momentum has been building around Viatris.
If this kind of clinical and financing news has your attention, it can be useful to widen the lens and see what else is moving in healthcare, including 40 healthcare AI stocks
With Viatris shares up 86.25% over the past year and trading only about 6.7% below the average analyst price target, the key question now is whether you are still early to the story or if the market is already pricing in future growth.
Most Popular Narrative: 57.4% Undervalued
Viatris last closed at $16.70, while the most followed narrative on the stock assigns a fair value of $39.24, implying a large valuation gap that some investors are watching closely.
Today, Viatris stands in a very different position than its stock price suggests. The company is extremely undervalued, trading at a forward P/E around 5, offering a solid dividend, and finally showing signs of a sustained recovery. If the transformation continues, with growth in new products, further debt reduction, and a market rerating, the bull scenario price target sits between $16 and $18, reflecting meaningful upside from current levels.
According to Adje1959, this fair value rests on a mix of steady revenue expectations, higher profit margins and a materially different profit multiple than the market is using today. The narrative leans heavily on how cash flow and earnings could evolve once the current transition phase settles, and how that might justify a much higher valuation than current pricing suggests.
Result: Fair Value of $39.24 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Viatris still faces key risks, including pressure from generic competition on mature products and the fact that it recently reported a net loss of $296.5m.
Find out about the key risks to this Viatris narrative.
Next Steps
With a mix of optimism around Viatris and clear risks in the background, it may be helpful to act now and form your own balanced view, starting with the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Viatris?
If Viatris has sharpened your curiosity, do not stop here. The market is full of other opportunities that could fit your goals just as well.
- Spot potential bargains early by scanning 43 high quality undervalued stocks that pair attractive pricing with solid fundamentals.
- Strengthen your income focus by reviewing 7 dividend fortresses that prioritize reliable, higher yielding payouts.
- Dial down portfolio stress by filtering for 75 resilient stocks with low risk scores that aim for resilience when conditions get choppy.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com